AJR Review Endorses Advanced Imaging Techniques, Validating Imaging Biometrics’ Tools for Brain Tumor Assessment

Imaging Biometrics, LLC (IB) has welcomed the release of a newly published expert consensus in the American Journal of Roentgenology (AJR) (DOI: 10.2214/AJR.23.30612), which highlights a vital issue in neuro-oncology: conventional MRI alone is insufficient for accurately evaluating treatment response in patients with high-grade gliomas. The AJR Expert Panel now formally recommends the regular use of dynamic susceptibility contrast MRI (DSC-MRI) to distinguish true tumor progression from treatment-related effects—a core capability of IB’s technology, including IB Neuro and its Fractional Tumor Burden (FTB) maps.

This endorsement closely mirrors the mission and achievements of Imaging Biometrics, whose validated imaging solutions have long played a role in clinical decision-making. IB Neuro, the company’s flagship software, uses DSC-MRI to generate quantitative relative cerebral blood volume (rCBV) maps and FTB maps, which have been independently shown to identify regions of active tumor versus treatment effects with high spatial precision.

Unlike traditional imaging approaches that rely on single-value metrics, FTB maps offer a per-voxel analysis of the entire lesion. This detailed, automated view enables clinicians to understand the spatial complexity and heterogeneity of brain tumors more clearly and reproducibly.

FTB maps are proving especially useful beyond monitoring treatment response over time—they’re also gaining traction among neurosurgeons for guiding biopsies and surgical plans. The fine-grained, voxel-level resolution helps distinguish viable tumor tissue from areas affected by therapy, enhancing surgical confidence and accuracy. In lesions with mixed or ambiguous appearance, this insight can lead to more targeted biopsies and more effective resection strategies.

“This AJR publication reinforces what our clinical partners have long known — DSC is essential for accurate response assessment for brain tumors,” said Michael Schmainda, CEO of IB. “We’re proud to offer a solution that not only meets the panel’s recommendations but exceeds them in terms of automation, standardization, and clinical impact.”

A key advantage of IB Neuro is its standardized processing pipeline for rCBV, which eliminates the need for manually placed reference ROIs (regions of interest). This removes a significant source of variability and ensures consistent results across different imaging platforms and institutions. Such standardization is critical in the context of multi-center clinical trials and long-term patient follow-up, where accuracy and reproducibility are paramount.